陈伟翔,郭素峡,羊镇宇,吴雄波,曹华明

• 1:南京医科大学附属无锡人民医院心血管内科

摘要(Abstract)：

<正>动脉血栓形成是急性冠状动脉综合征(ACS)和经皮冠状动脉介入治疗(PCI)后发生不良心血管事件的基本原因[1]。内皮破损导致的血小板活化及聚集是引起ACS等血栓事件最重要的病理过程。多项临床试验已证实ACS和(或)PCI术后患者应用阿司匹林和二磷酸腺苷(ADP)P2Y12受体拮抗剂的双联抗血小板治疗获益显著。然而,PCI术后血栓事件仍有发生,可能与抗血小板作用的延迟、PCI初期不能提供充分的拮抗作用及个体最大平均有效剂

关键词(KeyWords)： 急性冠状动脉综合征;血小板功能检测;抗血小板治疗

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 陈伟翔,郭素峡,羊镇宇,吴雄波,曹华明

参考文献(References)：

• [1]Wu Y,Ahmad SS,Zhou J,et al.The disulfide isomerase Erp57mediates platelet aggregation,hemostasis,and thrombosis.Blood,2012,119:1737-1746.
• [2]Liang ZY,Han YL,Zhang XL,et al.The impact of gene polymorphism and high on-treatment platelet reactivity on clinical followup:outcomes in patients with drug-eluting stent implantation.Eurolntervention,2013,9:316-327.
• [3]邱林,龚艳君.血栓弹力图在经皮冠状动脉介入治疗中的应用.中国介入心脏病学杂志,2014,22:582-585.
• [4]Sofi F,Marcucci R,Gori AM,et al.Clopidogrel non-responsiveness and risk of cardiovasuclar morbidity:an updated meta-analysis.Thrombo Haemost,2010,103:841-848.
• [5]Breet NJ,van Werkum JW,Bouman HJ,et al.Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation.JAMA,2010,303:754-762.
• [6]Patti G,Pasceri V,Vizzi V,et al.Usefulness of Platelet Response to Cldpidogrel by Point-of-Care Testing to Predict Bleeding Outcomes in Patients Undergoing Percuataneous Coronary Intervention(from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).Am J Cardiol,2011,107:995-1000.
• [7]Nguyen T,Diodati JG,Pharand C.Resistance to clopidogrel:a review of the evidence.J Am Coll Cardiol,2005,45:1157-1164.
• [8]Montalescot G,Wiviott SD,Braunwald E,et al.Prasugrel compared with clopidogrel inpatients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction(TRITONTIMI 38):double-blind,randomised controlled trial.Lancet,2009,373:723-731.
• [9]Wallentin L,Becker RC,Budaj A,et al.Ticagrelor versus clopidogrel in patients with acute coronary syndromes.N Engl J Med,2009,361:1045-1057.
• [10]Marcucci R,Gori AM,Paniccia R,et al.Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reacvivity to ADP detected by a point-of-care assay:a 12 months follow up.Circulation,2009,119:237-242.
• [11]Bates ER,Lau WC,Angiolillo DJ.Clopidogrel-drug interactions.J Am Coll Cardiol,2011,57:1251-1263.
• [12]FDA clopidogrel boxed warning.http://www.fda.gov/Drugs/Drugsafety/PostmarketDrugSafetyInformationforPatientsandProvid ers/DrugSafetyInormationgforHeathcareProfessionals/ucm190787.htm.Last access October 2013.
• [13]Brar SS,ten Berg J,Marcucci R,et al.Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention.A collaborative meta-analysis of individual participant data.J Am Coll Cardiol,2011,58:1945-1954.
• [14]Stone GW,Witzenbichler B,Weisz G,et al.Platelet reactivity and clinical outcomes after coronary artery implantation of drug eluting stents(ADAPT-DES):a prospective multicentre registry study.Lancet,2013,382:614-623.
• [15]Rollini F,Tello-Montouliu A,Angiolillo DJ.Advances in platelet function testing assessing bleeding complications in patients with coronary artery disease.Platelets,2012,23:537-551.
• [16]Gurbel PA,Erlinge D,Ohman EM,et al.Platelet Function Substudy Investigators.Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization:the TRILOGY ACS platelet function substudy.JAMA,2012,308:1785-1794.
• [17]Price MJ,Berger PB,Teirstein PS,et al.Standar-vs highdose clopidogrel based on platelet function testing after percutaneous coronary intervention:the GRAVITAS randomized trial.JAMA,2011,305:1097-1105.
• [18]Trenk D,Stone GW,Gawaz M,et al.A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents:results of the TRIGGERPCI(Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Altemative Therapy With Prasugrel)study.J Am Coll Cardiol,2012,59:2159-2164.
• [19]Collet JP,Cuisset T,RangéG,et al.Bedside monitoring to adjust antiplatelet therapy for coronary stenting.N Engl J Med,2012,367:2100-2109.
• [20]Bonello L,Camoin-Jau L,Arques S,et al.Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance:a multicenter randomized prospective study.J Am Coll Cardiol,2008,51:1404-1411.
• [21]Cuisset T,Frere C,Quilici J,et al.Glycoprotein IIb/IIIa inhibitors improve outcome after coronary stenting in clopidogrel nonresponders:a prospective,randomized study.JACC Cardiovasc Interv,2008,1:649-653.
• [22]Valgimigli M,Campo G,de Cesare N,et al.Intensifying platelet inhibition with tirofi ban in poor responders to aspirin,clopidogrel,or both agents undergoing elective coronaryintervention:results from the double-blind,prospective,randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.Circulation,2009,119:3215-3222.
• [23]Siller-Matula JM,Francesconi M,Dechant C,et al.Personalized antiplatelet treatment after percutaneous coronary intervention:the MADONNA study.Int J Cardiol,2013,167:2018-2023.
• [24]O'Gara PT,Kushner FG,Ascheim DD,et al.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction.A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation,2013,127:e362-e425.
• [25]Anderson JL,Adams CD,Antman EM,et al.2012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for he management of patients with unstable angina/non-STelevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.J Am Coll Cardiol,2013,61:e179-e347.
• [26]Hamm CW,Bassand JP,Agewall S,et al.ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:The Task Force for the management of acute coronary syndromes(ACS)in patientspresenting without persistent ST-segment elevation of the European Society of Cardiology(ESC).Eur Heart J,2011,32:2999-3054.